BioTuesdays
biophytis

HCW starts Biophytis at buy; PT $15

H.C. Wainwright initiated coverage of Biophytis SA of France (NASDAQ:BPTS) with a “buy” rating and $15 price target. The stock closed at $6.09 on Oct. 22. As a spin-off from Sorbonne University in 2006, Biophytis has...

Atea Pharmaceuticals

SVB Leerink cuts Atea Pharma PT to $20 from $60

SVB Leerink slashed its price target for Atea Pharmaceuticals (NASDAQ:AVIR) to $20 from $60 but maintained its “outperform” rating after the company’s Phase 2 MOONSONG trial in COVID-19 outpatients did not hit its...

Neuronetics Logo

BTIG cuts Neuronetics to neutral

BTIG downgraded Neuronetics (NASDAQ:STIM) to “neutral” and removed its price target, citing disappointing third quarter preliminary revenue and “perplexing fourth quarter guidance.” The stock closed at $6.40 on Oct. 12...

Clarus-Therapeutics

Maxim starts Clarus Therapeutics at buy; PT $13

Maxim Group initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with a “buy” rating and $13 price target. The stock closed at $5.61 on Sept. 28. Clarus is a commercial-stage company marketing Jatenzo, an oral...

Icosavax

WB starts Icosavax at outperform

William Blair launched coverage of Icosavax (NASDAQ:ICVX) with an “outperform” rating. The stock closed at $34.09 on Aug. 20. “We believe Icosavax stands to benefit from both the medical and investment communities’...

CTIBiopharmaLogo

BTIG starts CTI Biopharma at buy; PT $7

BTIG initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $7. The stock closed at $2.80 on Aug. 6. CTI is a biotechnology company engaged in the development of therapeutics for blood...

Arcturus Logo

Cantor starts Arcturus Therapeutics at OW; PT $71

Cantor Fitzgerald launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with an “overweight” rating and $71 price target. The stock closed at $35.94 on July 1. Arcturus is leveraging its proprietary lipid-based...